Sáez-Orellana F, Godoy P A, Bastidas C Y, Silva-Grecchi T, Guzmán L, Aguayo L G, Fuentealba J
Laboratory of Screening of Neuroactive Compound, Physiology Department, Faculty of Biological Sciences, Universidad de Concepción, Concepción, Chile.
Neurophysiology Laboratory, Physiology Department, Faculty of Biological Sciences, Universidad de Concepción, Concepción, Chile.
Neuropharmacology. 2016 Jan;100:116-23. doi: 10.1016/j.neuropharm.2015.04.005. Epub 2015 Apr 17.
Recent studies suggest that the toxic effects of Aβ can be attributed to its capability to insert in membranes and form pore-like structures, which are permeable to cations and molecules such as ATP. Our working hypothesis is that Aβ increases extracellular ATP causing activation of P2X receptors and potentiating excitatory synaptic activity. We found that soluble oligomers of β-amyloid peptide increased cytosolic Ca(2+) 4-fold above control (415 ± 28% of control). Also, ATP leakage (157 ± 10% of control) was independent of extracellular Ca(2+), suggesting that ATP traveled from the cytosol through an Aβ pore-mediated efflux and not from exocytotic mechanisms. The subsequent activation of P2XR by ATP can contribute to the cytosolic Ca(2+) increase observed with Aβ. Additionally, we found that β-amyloid oligomers bind preferentially to excitatory neurons inducing an increase in excitatory synaptic current frequency (248.1 ± 32.7%) that was blocked by the use of P2XR antagonists such as PPADS (Aβ + PPADS: 110.9 ± 18.35%) or Apyrase plus DPCPX (Aβ + inhibitors: 98.97 ± 17.4%). Taken together, we suggest that Aβ induces excitotoxicity by binding preferentially to excitatory neuron membranes forming a non-selective pore and by increasing intracellular calcium by itself and through P2XR activation by extracellular ATP leading to an augmention in mEPSC activity. All these effects were blocked with a non-specific P2XR antagonist, indicating that part of the neurotoxicity of Aβ is mediated by P2XR activation and facilitation of excitatory neurotransmitter release. These findings suggest that P2XR can be considered as a potential new target for the development of drugs or pharmacological tools to treat Alzheimer's disease. This article is part of the Special Issue entitled 'Synaptopathy--from Biology to Therapy'.
最近的研究表明,Aβ的毒性作用可归因于其插入细胞膜并形成孔状结构的能力,这些孔状结构对阳离子和ATP等分子具有通透性。我们的工作假设是,Aβ会增加细胞外ATP,导致P2X受体激活并增强兴奋性突触活动。我们发现,β-淀粉样肽的可溶性寡聚体使胞质Ca(2+)比对照增加了4倍(为对照的415±28%)。此外,ATP泄漏(为对照的157±10%)与细胞外Ca(2+)无关,这表明ATP是从胞质溶胶通过Aβ孔介导的外流而非胞吐机制流出的。ATP随后对P2XR的激活可能导致了Aβ所观察到的胞质Ca(2+)增加。此外,我们发现β-淀粉样寡聚体优先结合兴奋性神经元,导致兴奋性突触电流频率增加(248.1±32.7%),而使用P2XR拮抗剂如PPADS(Aβ + PPADS:110.9±18.35%)或Apyrase加DPCPX(Aβ + 抑制剂:98.97±17.4%)可阻断这种增加。综上所述,我们认为Aβ通过优先结合兴奋性神经元膜形成非选择性孔,并通过自身增加细胞内钙以及通过细胞外ATP激活P2XR导致微小兴奋性突触后电流(mEPSC)活动增强,从而诱导兴奋性毒性。所有这些效应都被一种非特异性P2XR拮抗剂阻断,表明Aβ的部分神经毒性是由P2XR激活和兴奋性神经递质释放的促进所介导的。这些发现表明,P2XR可被视为开发治疗阿尔茨海默病的药物或药理学工具的潜在新靶点。本文是名为“突触病变——从生物学到治疗”的特刊的一部分。